论文部分内容阅读
本文总结我院1976—1982年80例小细胞末分化型肺癌用环磷酰胺、长春新碱(CO):环磷酰胺、长春新碱、氨甲喋呤(COM):环磷酰胺、长春新碱、氨甲喋呤、强的松(COMP’):环磷酰胺、长春新碱、氨甲喋呤,甲基苄肼(COMP)四种方案的疗效。客观缓解率分别为20.1％、33.4％、27.8％、37.8％,中位生存时间:有效者分别为10月、10月、7.75月、12.16月,无效者分别为3月、5月、4.8月、3.8月,3年生存单化组0％,0％、0％、13.8％。毒性:恶心、呕吐、白细胞减少,血小板减少为主要副作用。四组方案中以COMP方案略重。分析本组资料:维持治疗与生存期有明显关系。维持治疗时间以超过3年为宜
This review summarizes the use of cyclophosphamide, vincristine (CO), cyclophosphamide, vincristine, methotrexate (COM): cyclophosphamide, vincristine, methotrexate in 80 patients with small cell-differentiated lung cancer from 1976 to 1982 in our hospital. Prednisone (COMP’): efficacy of four regimens of cyclophosphamide, vincristine, methotrexate, and methyl benzoate (COMP). The objective remission rates were 20.1%, 33.4%, 27.8%, and 37.8%, respectively. The median survival time was effective in October, October, 7.75, and 12.16 months. Invalid persons were in March, May, and 4.8 months respectively. In 3.8 months, 0% of the three-year survival unitized groups were 0%, 0%, and 13.8%. Toxicity: nausea, vomiting, leukopenia, and thrombocytopenia are the major side effects. In the four groups of programs, the COMP scheme is slightly heavier. Analysis of this group of data: maintenance treatment and survival have a clear relationship. It is advisable to maintain treatment for more than 3 years